A 58-year-old female with history of metastatic breast cancer presented to clinic.
This case highlights the ability of the T2Bacteria® Panel to provide rapid species identification and detection of the causative organisms when blood cultures do not, including polymicrobial infections.
This high risk, immunocompromised patient was initially treated with ceftriaxone and azithromycin for empiric treatment of pneumonia. Rapid species identification prompted escalation of therapy to the anti-pseudomonal antibiotic, cefepime. The patient defervesced the day after therapy escalation and continued to clinically improve with cefepime continuation until hospital discharge. Without the availability of T2Bacteria, the patient may have remained on inappropriate therapy for days until further clinical deterioration may have led to an empiric switch/broadening of therapy
A 58-year-old female with history of metastatic breast cancer presented to clinic with shortness of breath, fever, and pancytopenia. She was then admitted to the hospital with orders for blood cultures, T2Bacteria and empiric antibiotics.
Patient Selection Criteria
Patient admitted to hematology-oncology unit with suspected blood stream infection
Evaluation and Treatment Decision
Empiric Therapy: ceftriaxone and azithromycin
T2Bacteria Result: Positive for P. aeruginosa and E. coli
Blood Culture Result: no growth
Chest x-ray: evidence of right lower lobe pneumonia
Decision making based on T2Bacteria Result
A rapid T2Bacteria result allowed for identification of the P. aeruginosa and E. coli bacteremia in a patient with culture negative infection. This prompted the prescriber to escalate therapy to cefepime for the coverage of the P. aeruginosa that was not identified via the blood culture.